HR 4191 · in committee · significant
MAPS Act
- healthcare
What this bill does
- The FDA must maintain and update a list of essential medicines needed during health emergencies and shortages.
- Drug manufacturers, healthcare providers, and patients relying on critical medications are affected by supply chain oversight.
- The FDA reviews the list every two years at no new appropriation, while HHS conducts annual supply chain vulnerability assessments.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How should the FDA prioritize which medicines to include on the essential medicines list during competing shortage scenarios?
- 02
What enforcement mechanisms would ensure drug manufacturers comply with supply chain vulnerability assessments without imposing excessive compliance costs?
- 03
If the FDA identifies supply chain vulnerabilities through annual assessments, what actions should HHS take to address them?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · D-CA-7
Doris O. Matsui
Citizen cosponsors
0
In Congress
1/ 435
House Reps cosponsoring
Introduced 2025-06-26
Joining the bill
Legislative timeline
2025-06-26 · house · IntroReferral
Referred to the House Committee on Energy and Commerce.
2025-06-26 · IntroReferral
Introduced in House
2025-06-26 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.